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ABBREVIATIONS
FIRES Febrile infection related
epilepsy syndrome
KD-PN Ketogenic diet parenteral
nutrition
KDT Ketogenic diet therapy
AIM To give evidence-based recommendations on the application of ketogenic diet
parenteral nutrition (KD-PN) in emergency situations.
METHOD An international group of experts (n=14) researched the literature and distributed a
survey among 150 expert centers. International accepted guidelines (European Society for
Clinical Nutrition and Metabolism/European Society for Paediatric Gastroenterology
Hepatology and Nutrition and the American Society for Parenteral and Enteral Nutrition) and
handbooks for parenteral nutrition were considered general standards of care.
RESULTS In the literature, we identified 35 reports of patients treated by KD-PN. International
guidelines and handbooks provided some conflicting information. Twenty-four expert teams
from nine countries responded to the survey, reflecting the limited clinical experience.
INTERPRETATION This paper highlights 23 consensus-based recommendations for safe and
effective KD-PN (e.g. diet initiation, calculation, application, monitoring, and evaluation)
based on the best evidence available and expert opinions.
Ketogenic diet therapy (KDT) is a dietary treatment with
an established efficacy in children and adolescents for
drug-resistant epilepsy and metabolic disorders (e.g. glu-
cose transporter 1 deficiency and pyruvate dehydrogenase
deficiency).1–5 Ketogenic diets can differ in macronutri-
tional composition: the ratio between ketone producing
(fat) and non-ketone producing (carbohydrates plus pro-
tein) nutrients varies between 3.0:1 and 4.0:1. Modified
versions of KDT (e.g. the modified Atkins diet, low glyce-
mic index diet) are designed to promote compliance with-
out compromising the effect on seizure reduction.6 There
are many ways to administer KDT. In most cases, KDT is
given by an enteral diet (orally or by nasogastric tube/per-
cutaneous endoscopic gastrostomy) that is tailored to each
individual. It requires detailed calculations of the diet to
ensure that both adequate energy for growth and micronu-
trient requirements are met while ketosis is reached. In
some rare conditions such as refractory status epilepticus
or febrile infection related epilepsy syndrome (FIRES),
KDT needs to be started and sometimes provided through
parenteral administration. Parenteral nutrition may also be
indicated in the acute setting during temporary or, more
rarely, chronic digestive dysfunction in pre- or postopera-
tive procedures.
Recently updated international guidelines (European
Society for Clinical Nutrition and Metabolism/European
Society for Paediatric Gastroenterology Hepatology and
Nutrition7,8 and the American Society for Parenteral and
Enteral Nutrition)9,10 on parenteral nutrition are not appli-
cable to KDT for the amount of carbohydrates recom-
mended to initiate ketosis. There are currently limited data
available on ketogenic diet parenteral nutrition (KD-PN),
with only 35 cases reported in the literature.11–19 Only the
White Paper from the Charlie Foundation provides brief
recommendations for KD-PN practice.20
This paper highlights recommendations based on the
best evidence combined with opinions of an international
group of experts. Consensus was reached on recommenda-
tions for achieving safe and effective KD-PN to facilitate
ketosis with the highest diet ratio possible associated with
the lowest level of complications. These recommendations
will benefit clinical practice for multidisciplinary teams
(dieticians and clinical staff in ketogenic diet expert teams
and intensive care units) involved in KD-PN.
METHOD
An international multidisciplinary team of experts in KDT
(n=14) was established at the International Ketogenic
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Symposium in Banff, Canada, in 2016. A project group
(n=7) was launched to address the subject using a survey of
current practice in KD-PN, a literature search, and the
standard of care for parenteral nutrition.
International survey
The survey was distributed to 150 registered dieticians
working in KDT throughout the world. The goal was to
establish recommendations for safe international KD-PN
practice and to identify areas requiring further research.
Twenty-four centers from nine different countries (Canada,
England, France, Denmark, Germany, Ireland, the Nether-
lands, Sweden, and USA) responded to the survey.
In addition, a literature search was compiled from 1995
to 2018 using the keywords ‘ketogenic diet’ and ‘par-
enteral’ in PubMed. Abstracts were reviewed to select pub-
lications in humans only. The papers were then read to
identify patients treated by KD-PN.
The project group (n=7) wrote an initial text that was
reviewed by the review group (n=7). After two rounds of
review, consensus agreement was reached on the final text,
resulting in 23 KD-PN recommendations. In medical prac-
tice the application of these KD-PN recommendations has
to be tailored to the medical protocol of each expert center.
It is strongly recommended that centers implementing KDT
parenterally have previous experience in enteral KDT.
Literature search
A literature search in PubMed identified 35 reported
patients treated with KD-PN from 1970 to 2018 (Table I).
In most cases, the use of KD-PN was only for a few days
(Table I). The KD-PN was then replaced by enteral
administration of KDT. The use of parenteral nutrition was
related to acute illnesses resulting in intestinal ileus, severe
vomiting, or severe diarrhea. Few cases reported prolonged
use of parenteral ketogenic diet because of conditions in
which the use of the enteral route was challenging.16,19
There are currently no data allowing an evaluation of
the level of efficacy of parenteral and enteral administra-
tion of KDT. The available data from the 35 reported
patients show that parenteral ketogenic diet allows the
patient to reach a state of ketosis, which is a hallmark of
KDT treatment. There are also data reporting the experi-
ence of various teams in initiating KDT by parenteral
administration and switching to enteral administration after
a few days.
The use of KD-PN may lead to side effects such as
hypertriglyceridemia or an increase in pancreatic and liver
enzymes (Table I). The exact significance of these changes
is not established, nor whether they are transient or long
term. These parameters should be carefully monitored and
actively managed. It is assumed that the use of KDT by
parenteral administration is associated with the same risk
as regular total parenteral nutrition such as sepsis and
catheter thrombosis (the authors’ expert opinion).
Table I: Overview of studies and case reports of ketogenic parenteral nutrition
Number
of patients Indication Duration Adverse events
Rosenthal et al.11 1 Gastrointestinal problems during KDT 4mo Sepsis at 4mo
Roan12 1 Gastrointestinal: protein losing
enteropathy during KDT
12mo (with minimal
enteral nutrition)
No
Jung et al.13 10 Gastrointestinal problems during KDT 4.1d (mean)
Range 2.6–5.6d
All: hypertriglyceridemia
n=1: increased pancreatic enzymes
n=1: increased liver enzymes
Strzelcyk et al.14 1 Status epilepticus: nasogastric tube
not tolerated
27d Not reported
Lin et al.15 1 SRSE: gastrointestinal (bleeding) 8d (5 exclusive TPN) Hypertriglyceridemia
Increased pancreatic enzymes
Chiusolo et al.16 1 RSE: gastrointestinal problems 8d (3 exclusive TPN) Increased levels of amylase, lipase,
liver enzymes, and triglycerides
Appavu et al.17 1 RSE Not available No
Farias-Moeller et al.18 2 RSE 15d
8d
Hypertrigliceridemia and HLH
Hypertrigliceridemia and pancreatitis
Dressler et al.19 17 Status epilepticus: n=3
Surgery: n=9
Illness with gastrointestinal: n=2
Feeding difficulties: n=3
13/17 were already on ketogenic diet
3d
(IQR 2–4d)
(range 1–41d)
n=3: transient hypertriglycerides
n=5: hypercholesterol
n=1: transient GGT
n=1: GOT
n=2: GPT
n=4: lactate dehydrogenase
KDT, ketogenic diet therapy; SRSE, super-refractory status epilepticus; TPN, total parenteral nutrition; RSE, refractory status epilepticus;
HLH, hemophagocytic lymphohistiocytosis; IQR, interquartile range; GGT, c-glutamyl transferase; GOT, glutamate–oxaloacetate transami-
nase; GPT, glutamate pyruvate transaminase.
What this paper adds
• In acute settings, ketogenic diet therapy (KDT) can be administered parenter-
ally.
• Parenteral administration of KDT should be started only at the intensive care
unit.
• Initiate ketogenic parenteral nutrition stepwise to the highest ratio possible
with the lowest level of complications.
• Evaluate the risk–benefit ratio of parenteral administration continuously.
• Restart enteral feeding as soon as appropriate.
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RECOMMENDATIONS
The 23 recommendations for the application of KD-PN
are listed in Table II.
Preparing for treatment
In general, the indications and contraindications (e.g. fatty
acid oxidation deficiencies) of KDT should be similar for
both parenteral and enteral dietary use.1 However, there
are two main conditions when the use of KDT should be
considered parenterally: when enteral feeding is not possi-
ble in a child already on KDT (with the aim of maintain-
ing ketosis and anti-seizure effect) or when KDT is
initiated in a patient who cannot be enterally fed (with the
aim of reducing their seizures). In recent years, the use of
KDT for refractory status epilepticus and FIRES has been
increasingly reported.21–23 In this acute setting, KDT is
usually administered by an enteral route (46 of 47 pediatric
cases reported by Chiusolo et al.).16 However, few patients
may require parenteral administration. On the basis of the
risk–benefit ratio, enteral KDT should be prioritized
before considering KD-PN (the overall risk of parenteral
nutrition and side effects are reported in Table I).
It is generally accepted that parenteral nutrition should
be considered when an infant or child is not able to receive
enteral feeding for more than 48 hours.9,10,24 When start-
ing KDT for the first time in the acute setting, to maxi-
mize its potential for ketosis, additional fasting for
24 hours may be appropriate. This should be conducted
under careful monitoring of glucose and ketone levels.
Parenteral administration of KDT should not be used in
infants born preterm as they are a high-risk group for mal-
nutrition and complications.
Table II: Summary of 23 recommendations for application of KD-PN
Ketogenic parenteral nutrition should only be started in an intensive care unit
1. In general, indications and contraindications (e.g. fatty acid oxidation deficiencies) for KD-PN and enteral KDT are similar
2. Start parenteral administration of KDT exclusively in case nothing by mouth >48h is expected
3. Check for contraindications in case of a newly starting KDT
4. Careful evaluation of the medical and nutritional status: infants born preterma and malnourished children are at high risk of
complications and therefore KD-PN should be omitted
5. Change all medications to non-carbohydrate forms if possible (pill, tablet, pharmacy compounded). Consider using toothpaste with the
lowest glycerol and carbohydrate content. The carbohydrate and alcohol content of the intravenous product should be calculated into the
final KD-PN diet ratio
6. Additional fasting can be performed at KDT initiation for a maximum of 24h to induce ketosis for first-time KDT initiation. Note:
hyperketosis and/or hypoglycemia might be accelerated by caloric restriction
7. Obtain baseline nutritional assessment: use ideal weight/height and height/age
8. Fluid: determine the net fluid volume available for parenteral nutrition. Notice the medical status, body weight, excretion, blood
electrolytes, acid base status, hematocrit, specific gravity of urine, and urine electrolytes
9. Calories: start with 50% of goal and build this up within a maximum of 1wk when lipids are increased. Aim for resting energy
expenditure or 70–80% of calculated energy requirements. Intake of 50% of calculated energy goal might be accepted for a limited period
(3–4d). If available, measure resting energy expenditure and respiratory quotient. Notice the risk of hyperalimentation
10. Carbohydrates: the use of glucose/dextrose might be avoided for 3–4d at KD-PN initiation to benefit ketosis, when this is clinically
appropriate as a certain amount of carbohydrates will be delivered by glycerol metabolization from intravenous lipid emulsions.
Administer sodium chloride 0.45% or other fluids required on the basis of blood electrolytes. Subsequently, on the basis of ketone and
glucose levels and laboratory checks, use the lowest dextrose percentage available or start dextrose 5% solution delivering the amount of
carbohydrates of the original enteral ketogenic diet as the maximum
11. Protein: aim for 100% requirements as the goal, with 1.5g/kg/d as a minimum requirement. To maximize ketosis, 0.5–0.8g/kg/d
temporary restriction is accepted. During critical illness, additional protein may be required to promote positive nitrogen balance
12. Lipids: start with 50% of goal lipids or 1–2g/kg/d. Increase lipids every 1–2d (on the basis of triglyceride level) up to a maximum of
4g/kg/d. Run lipids continuously. Notice possible allergy or hypersensitivity of the patient to fish, egg, soybean, or peanut protein
13. Diet ratio: start with 1:1 ratio and increase every 1–2d to the highest ratio possible. Aim for a diet ratio within the range 2.0:1–2.9:1
(including glycerol from lipid emulsion) within 3–4d. Aim for the highest diet ratio possible with the lowest level of complications.
Consider carnitine supplementation (50mg/kg to a maximum of 1000mg/d) to benefit ketosis
14. Vitamin/mineral supplementations should be age-appropriate, and consider the weight of the patient
15. Delayed treatment (after 7d) should be avoided for children already on ketogenic diet (to maintain ketosis) or when KDT is required
urgently (to reach ketosis) for epilepsy control (RSE or FIRES)
16. Appropriate level of ketosis might not always be achieved; when seizure burden improves this might be accepted
17. Use ASPEN and ESPGHAN/ESPEN guidelines to prevent general complications of parenteral nutrition
18. Side effects of parenteral nutrition during KDT that are most frequently observed are elevated lipids (up to <400mg/dL per 10mmol/L),
insufficient ketosis (<1.5mmol/L), hypoglycemia (<2.5mmol/L per 45mg/dL). To a smaller degree: hyperketosis (>6.5mmol/L),
hyperbilirubin (>40lmol/L), altered liver function tests, and pancreatic enzymes
19. A tailored nutritional regimen must be carefully chosen and closely monitored
20. KD-PN initiation during propofol anesthesia is not recommended and should be undertaken only with caution
21. Close monitoring should be completed at baseline, maintained during follow-up, and tailored to the patient’s medical and nutritional
status
22. Evaluation will be based on the maintenance of seizure control provided by the initial enteral prescription of the ketogenic diet; in the
case of RSE or FIRES, the efficacy should be evaluated both clinically and electroencephalographically
23. Transition to an enteral feed has to be tailored to the medical situation and nutritional status. Start trophic feeds as soon as possible
and appropriate
aInfants born preterm: <36wks postmenstrual age. KD-PN, ketogenic parenteral nutrition; KDT, ketogenic diet therapy; RSE, refractory sta-
tus epilepticus; FIRES, febrile infection related epilepsy syndrome; ASPEN, American Society for Parenteral and Enteral Nutrition; ESP-
GHAN, European Society for Paediatric Gastroenterology Hepatology and Nutrition; ESPEN, European Society for Clinical Nutrition and
Metabolism.
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A thorough nutrition assessment with anthropometric
data must be completed before starting KD-PN. Possible
allergies or hypersensitivities must be identified. The nutri-
tional implications of both parenteral nutrition and KDT
should be discussed with the patient’s medical team and
the goals of parenteral nutrition and KDT at this critical
time determined.
All medications, including those administered intra-
venously, should be converted to the lowest carbohydrate
form. Intravenous products are often mixed with dextrose
or may provide calories, which can affect ketosis nega-
tively. Careful consideration is needed when prescribing
intravenous medications (e.g. pentobarbital delivers carbo-
hydrates from both glycerol and alcohol). Collaboration
with a pharmacist is essential to determine the total carbo-
hydrate content of all medications before initiating treat-
ment. Other points to consider might be the carbohydrate
content of toothpaste used. For most patients, switching
from liquid, enterally provided anti-seizure drugs to tablets
or intravenous preparations is sufficient. The pharmacist
should also carefully check the nutritional composition of
the lipid brands in case of allergies.
Dietary prescription
Fluid
In medical practice, the total volume of parenteral nutri-
tion is a factor limited by the volume required to dilute
the wide range of medications used during admission to
the intensive care unit.9,10,25 Fluid requirements vary and
must be tailored to the patient’s medical situation, body
weight, excretion, blood electrolytes, acid–base status,
hematocrit, specific gravity of urine, and urine elec-
trolytes.24 Table III shows the recommendations for calcu-
lating fluid intake.26
Results from our survey did not include any recommen-
dations on fluid requirements (Appendix S1, online sup-
porting information).
Calories
International guidelines on parenteral nutrition agree that
100% intake of energy requirements may not always be
reached and requirements may vary depending on the
phase of the illness: they are significantly lower during the
acute and stable phases.27
If measurement of resting energy expenditure is feasible,
this is preferable to using equations for calculating caloric
intake. The caloric intake has to be tailored to individual
circumstances. Although the patient with FIRES might be
critically ill, the resting energy expenditure might be
reduced in sedative coma. Repeated measurements should
be obtained when the medical situation of the patient
changes (e.g. fever, inflammation). However, it is impor-
tant to avoid hyperalimentation because it may induce
metabolic imbalance, liver damage, and risk refeeding syn-
drome (particularly in severely malnourished patients).27,28
If measurement of resting energy expenditure at the inten-
sive care unit is not feasible, the Schofield equation for
weight can be used.27
In the literature, three studies reported reduced calorie
intake ranging from 50% to 75% of recommended daily
allowance.12,13,15 It seems that aiming for 50% of calories
as documented in some studies may be most feasible given
the low dextrose, low protein, and high fat content of the
KD-PN prescription.
Results from our international survey showed a high
variety in the way energy requirements are calculated in
clinical practice (e.g. 50–90% of recommended daily allow-
ance [21%], caloric intake depending on parenteral nutri-
tion volume [21%], measuring resting energy expenditure
[17%], Schofield equation [12%]) (Appendix S1).
The caloric intake that can be achieved on the basis of a
KDT composition might not always be realized.
Carbohydrates
International parenteral nutrition guidelines recommend a
glucose intake that covers 40% to 60% of non-protein
calorie intake, which is not applicable in KDT and KD-
PN.8–10 The permitted quantity of carbohydrate during
KDT follows from the calculation of energy and protein
requirements after establishing the necessary prescription
of fat.
To maintain the level of ketosis during KD-PN, the
daily carbohydrate intake from any previous oral ketogenic
diet should be used as a benchmark for the maximum
amount of carbohydrates prescribed in parenteral nutrition.
In clinical practice, for ketosis the ultimate glucose provi-
sion depends on a diet ratio of the maximal possible lipids
and minimal safe protein intake to prevent malnutrition.
To establish or maintain ketosis, the carbohydrate intake
might be sacrificed, resulting in exclusion of dextrose/glu-
cose solution during KD-PN (i.e. at diet initiation). Special
attention should be given to (young) children at risk of
hypoglycemia, especially during acute illness. Because most
KD-PN preparations will be non-inclusive of dextrose/glu-
cose or will contain under 5% dextrose/glucose, the glucose
infusion rate will be very low to 0mg/kg/min. In the case of
fluid restriction, a higher percentage of dextrose/glucose
might be required to establish an appropriate daily glucose
administration. However, some hospital inpatient pharma-
cies might not be able to formulate this because of mixing
and compounding devices and may require a small amount
of dextrose. Intravenous lipid emulsions contain a range of
2.2% to 2.5% glycerol which will also deliver carbohydrates
after metabolization. The end diet ratio will be different if
Table III: Consensus recommendations for daily fluid requirement
calculation
Goal
0–10kg: 100mL/kg/d
10–20kg: 1000mL+50mL/kg
20–40kg: 1500mL+20mL/kg
>40kg: use adult recommendations (or Holliday–Segar formula)
Minimum
75% of calculated enteral fluids
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these carbohydrates are considered.20 Moreover, intravenous
products (i.e. sedatives such as pentobarbital) deliver not
only carbohydrates by glycerol but also by alcohol.
In the literature, three studies used 5% dextrose in their
formulation and therefore cycled their parenteral nutrition
for a shorter period of time (for 16h and off for 8h) while
cycling sodium chloride 0.45% to decrease total carbohy-
drate allotment.13–15 This trend was most probably adapted
from each other’s experience.
Results from our international survey provided conflict-
ing information. From 24 centers, 58% did not calculate
glycerol as carbohydrate into diet ratio calculations. Sixty-
four per cent of the centers used a dextrose/glucose-free
solution at initiation; 42% of the centers started par-
enteral nutrition by using a low dextrose/glucose solution
(Appendix S1).
Protein
According to international parenteral nutrition guidelines,
the protein requirement is increased by as much as 20% to
50% in critical illness, thermal injury, and catch-up
growth. Critically ill patients are at risk of malnutrition
principally as a result of protein breakdown that is directly
related to the seriousness of their condition, which is more
profound at a very young age (infants and young children).
A minimal protein intake of 1.5g/kg ideal weight is essen-
tial to prevent malnutrition.24,28,29
In the literature, studies recommend aiming for 1g pro-
tein/kg/d but in daily practice an intake of 0.5g/kg to 0.8g/
kg seems to be more realistic.12,15 Only the study of Dress-
ler et al.19 reported a median protein intake of 2g/kg/d
with a range of 1.5g/kg to 2g/kg in KD-PN, owing to very
young age (median age of the children 1y 10mo), resulting
in a median diet ratio of 0.9:1. The White Paper from the
Charlie Foundation on ketogenic diet recommends 1.5g/kg
protein during stress but states an intake of 0.5g/kg to
0.8g/kg for short-term use might be acceptable.20
Results from our international survey showed 63% of
the 24 expert centers calculate more than 1g/kg into the
total parenteral nutrition prescription. It is unclear whether
they were able to reach the minimal amount of 1.5g/100k-
cal to prevent malnutrition (Appendix S1).
During KD-PN, optimizing the diet ratio to the maximum
limits the intake of adequate protein and carbohydrates.
Therefore, in clinical practice, priority is given to protein
intake to prevent malnutrition by the general omission of car-
bohydrates (when the glucose and ketone levels allow this).
Lipids
In KD-PN the delivery of lipids is of utmost importance
to ensure the optimal level of ketosis for seizure control.
In clinical practice this is challenging: side effects (i.e.
hyperlipidemia) might occur even with short-term use.
Lipids are an important component of parenteral nutrition
as they greatly contribute to the caloric intake in a low vol-
ume and low osmolarity so are suitable for peripheral infu-
sion. They also provide essential fatty acids.30
Intravenous lipid emulsions have varying ingredients;
therefore it is important to rule out allergies and hypersen-
sitivities before starting KD-PN. Several intravenous lipid
emulsions contain egg, olive, soybean, or peanut proteins,
which are contraindicated in such conditions.31
International guidelines recommend starting with a dose
of 1g/kg/d to 2g/kg/d advanced to 2.5g/kg/d to 3g/kg/d9,10
or to start with 2g/kg/d advanced to 3g/kg/d to 4g/kg/d.30
A continuous infusion, by central intravenous line, will be
better tolerated. In clinical practice the application of 4g/
kg/d will be essential to maximize the diet ratio.
In the literature, the case report of KD-PN by Roan12 and
the study by Jung et al.13 reported lipids of at least 4g/kg/d.
In the studies by Lin et al.15 and Dressler et al.19 the lipid
intake used was 3g/kg/d. The study by Dressler et al. of 17
infants reported that, despite a median diet ratio of 0.9:1
(SD 0.28; range 0.6–1.5), 10 out of 13 children who were
already on KDT were able to maintain their level of seizure
control during KD-PN and two out of four of the children
with de novo KD-PN experienced 50% and 86% seizure
reduction respectively. The White Paper recommends start-
ing with 2g/kg/d to 3g/kg/d advancing to 4g/kg/d.20
Results from our international survey showed that most
centers start with 1g/kg to 3g/kg (54%), increasing with
steps of 1g/kg to 1.9g/kg up to goal 3g/kg/d to 4g/kg/d
and run their parenteral nutrition lipids continuously. In
66.6% of the centers, carnitine is supplemented (50mg/kg,
with a maximum of 1000mg/d) to stimulate fatty acid oxi-
dation (Appendix S1).
A 4:1 diet ratio might not be achieved, depending on the
maximum lipids tolerated and the accompanying amount
of glycerol, but it might still be effective in reducing sei-
zures.
Vitamins and minerals
Parenteral vitamins and minerals are usually provided as
mixtures. Vitamins and minerals both pose particular phar-
macological problems. When given intravenously, some may
adhere to tubing or can be degraded by light. Also, the sta-
bility of the mixture and ‘ingredients’ might have an effect.
The actual amount of vitamins/minerals delivered to the
patient may therefore be lower than the intended dose.32–35
There are different manufacturers of vitamins and mineral
mixtures, and description depends on hospital/pharmacy
protocols.
In the literature, the case report of Roan12 used stan-
dard multivitamins and multi-electrolytes; it recom-
mended starting 2lg to 2.5lg selenium/kg/d to prevent
deficiency. In the event of long-term parenteral nutrition
use, it is recommended to add 1mg vitamin K/d, and in
the presence of diarrhea to add zinc (10–15mg/L of out-
put).36 Other studies have provided supplementation
according to international guidelines.32,33 The White
Paper on ketogenic diet gives no specific recommenda-
tions.20
Results from our international survey showed 20 out of
24 centers added a multivitamin (Appendix S1).
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Initiation
International guidelines (European Society for Paediatric
Gastroenterology Hepatology and Nutrition/European
Society for Clinical Nutrition and Metabolism7 and Ameri-
can Society for Parenteral and Enteral Nutrition)28 have
recently been evaluated. Their information on diet
Table IV: Overview of recommendations for monitoring. (a) Recommendations on baseline checks for newly starting KDT as parenteral nutrition.
(b) Recommendations on monitoring during KD-PN
(a)
Exclude contraindicated metabolic disorders (i.e. fatty acid oxidation disorders, carnitine deficiency [primary], carnitine
palmitoyltransferase I or II deficiency, carnitine translocase deficiency, pyruvate carboxylase deficiency)
Anthropometrics (weight, height, head circumference at <1y)
Dietary intake and output
Complete blood count with platelets
Electrolytes to include serum bicarbonate, total protein, calcium, zinc, selenium, magnesium, phosphate
Trace elements; zinc, selenium, copper, CRP
Serum liver and kidney tests (including albumin, AST, ALT, blood urea, nitrogen, creatinine)
Fasting lipid profile
Serum acylcarnitine profile
Urine analysis
Urine calcium and creatinine
Antiepileptic drug levels (if applicable)
During initiation
Glucose daily/every other day
b-hydroxyburyrate daily/every other day
(b)
Item
Age <1y
Unstable
Age <1y
Stable
Age >1y
Unstable
Age >1y
Stable
Weight Daily Weekly 29wk Weekly
Height Weekly Monthly 192wks 193mo
Head circumference 192wks Monthly — —
Intake/output Daily Daily Daily Daily
Seizures Daily Daily Daily Daily
Blood
Blood gas and osmolarity Daily 2–39wk Daily 29wk
Sodium, potassium, chloride Daily 2–39wk Daily 29wk
Calcium, magnesium, phosphorus Daily 2–39wk Daily 29wk
Copper Monthly Monthly Monthly Monthly
Complete blood count Unknown Weekly Unknown Weekly
Albumin Daily 29wk Daily Weekly
Glucosea 194h 2–49d 194–6h 1–39d
Billirubin total/direct Daily 29wk Daily Weekly
ASAT, ALAT, ALP 29wk 29wk Weekly Weekly
Amylase/lipase Unknown Weekly Unknown Weekly
Urea Daily Daily Daily 29wk
Creatinine Daily Daily Daily 29wk
Triglyceridesb Daily Weekly Daily Weekly
b-hydroxybutyratec Daily Daily Daily Daily
Carnitine free/total Unknown 196mo Unknown 196mo
Lipid profile Daily when lipids off for 4h Monthly Unknown Monthly
Hemoglobin Weekly Weekly Weekly Weekly
Serum ferritin Monthly Monthly Unknown Monthly
Vitamins A, D 25-OH Monthly Monthly Monthly Monthly
Vitamins B1, B12 Monthly Monthly Monthly Monthly
Folic acid, Zn, Al 196–12mo 196–12mo 196–12mo 196–12mo
Copper, chromium, manganese At indication At indication At indication At indication
Selenium Monthly 196mo Unknown 196mo
Urine
Sodium Weekly Monthly Monthly Monthly
Potassium Weekly Monthly Monthly Monthly
Calcium/creatinine ratio Weekly Monthly Weekly Monthly
Urine ketonesd (at indication) Daily 29d Daily 29d
Osmolarity Weekly Monthly Monthly Monthly
aGlucose levels of 2–2.5mmol/L (approximately 40–45mg/dL) should be treated immediately with 2–4g of carbohydrates (20–40mL glucose
10%). Blood glucose should be rechecked 15–20min after treatment and if not improved a further dose is given until the glucose level is
above 3mmol/L (approximately 55mg/dL).39 bThe upper limit for triglycerides is 10mmol/L (approximately 387mg/dL). At a level of 5mmol/L
(approximately 200mg/dL), start carnitine 50mg/kg with a maximum of 1g/d.40 cThe goal is within the range 2–5mmol/L b-hydroxybutyrate
(approximately 20–52mg/dL). dIdeal range is 8–16mmol/L or 3–4+; the exact level depends on the type of urine dipstick. KDT, ketogenic diet
therapy; KD-PN, ketogenic parenteral nutrition; CRP, C-reactive protein; AST, aspartate transaminase; ALT, alanine transaminase; ASAT,
aspartate aminotransferase; ALAT, alanine aminotransferase; ALP, alkaline phosphatase.
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initiation, side effects, and monitoring gives guidance
about parenteral nutrition in pediatric patients but has to
be evaluated from the perspective of KDT. If a patient is
unable to tolerate enteral nutrition and a ketogenic diet is
needed for anticonvulsant therapy, KD-PN needs to be
considered. The time at which KD-PN should be consid-
ered, however, is variable. The recently updated European
Society for Paediatric Gastroenterology Hepatology and
Nutrition/European Society for Clinical Nutrition and
Metabolism and American Society for Parenteral and Ent-
eral Nutrition guidelines recommend starting parenteral
nutrition when a patient is expected to be unable to restart
enteral feeding within 48 hours.24,28 A recent publication
has highlighted the benefits of delaying total parenteral
nutrition (by 7d) in the critically ill child; however, this is
still under debate and not yet general practice.37 Delayed
treatment might not be an option under KDT because
children either are already on KDT and should maintain
ketosis or require KDT urgently for acute seizure control
(drug-resistant ongoing repetitive seizures, refractory status
epilepticus, or FIRES).
The literature and our international survey clearly show
that during KD-PN a certain level of ketosis can be
reached within a few days. Monitoring of ketosis is prac-
ticed in both urine and/or blood and checked daily or
every other day. There are several ways of possible initia-
tion and it is not clear which is most effective
(Appendix S1).
Side effects and monitoring
The available international parenteral nutrition guidelines
include a description of side effects9,10,28,34 but do not pro-
vide specific information during KDT. When KDT is
established as parenteral nutrition treatment for refractory
status epilepticus or FIRES, adverse effects already known
during KDT initiation might occur (e.g. hypoglycemia,
constipation, hypertriglyceridemia, increased liver enzyme,
increased pancreatic amylase).
On the basis of the data from KD-PN studies11–19,38 and
in clinical practice, it is clear that, during KD-PN, side
effects are frequently documented even if parenteral nutri-
tion is only given for a few days.
The mixing of drugs with parenteral nutrition has to be
avoided on the basis of drug compatibility.34
Most side effects are transient and can be avoided by
the use of strict protocols in the intensive care unit.
This highlights the need for the slow introduction of
KD-PN based on the international parenteral nutrition
guidelines with tailoring of ratio, fat, protein, and carbo-
hydrate, and regular monitoring of liver function with
quick response to hyperketosis and hypoglycemia (e.g.
frequency of monitoring glucose and ketone levels tai-
lored to the medical and nutritional status). Initiation
during propofol anesthesia should be avoided owing to
the risk of propofol infusion syndrome caused by the
high triglyceride content of this anesthetic. If considered
necessary, it should be handled with caution with strict
Aim:       Ketogenic parenteral composition with the highest diet ratio possible with minimal complications and maximum effect on seizure reduction.
Step I:   Preparation Step II:  Design Step III:  Initiation Step IV:  Monitoring
Collect data of:
Medical history and background
Diagnosis.
Indication for KD therapy: 
-already on KD: level of seizure 
reduction     
-newly start KD: current level of 
seizures, contraindication.
Enteral route prohibited for 
>48h.  
Anthropometrics.
Acute medical situation.
Nutrition history/allergies.
Notice:
- Laboratory checks for contraindications.
- Malnutrition.
- Concomitant medication (IV).
- Carbohydrate content of medication (IV).
- Current enteral intake, output, and route.
Use international guidelines! 
--> Individualize for ketogenic therapy
Determine:
1. Fluid volume available for TPN
Notice : fluid for medication, fluid 
restriction, lab checks.
2. Caloric goal
Notice: BMR, risk for hyper alimentation.
3. Carbohydrate goal
Notice: dextro/glucose use, glycerol 
content.
4. Protein goal
Notice: malnutrition, acute illness, ideal 
weight.
5. Lipids/diet ratio goal
Notice: aim for the highest possible.
6. Additives
Notice: individualize for RDA age and/or 
weight.
7. Ketones
Notice: level of ketosis needed for seizure
reduction.
KD-PN prescription:
1. Write individualized step 
by step plan for initiation.
2. Follow hospital and 
pharmacy protocols and 
procedures except for 
carbohydrates and lipids. 
3. Start trophic feeds whenever 
possible.
Use international guidelines!
Screening for side effects:
1. Insufficient ketosis.
2. Hyperketosis.
3. Hypoglycemia.
4. Hyperlipids.
5. Minerals at risk.
(Ca, Mg, Ph)
6. Liver panel and pancreatic enzymes.
Notice:
- CVC infections.
- Anthropometrics.
- Seizure reduction.
- Medical situation.
- Complications in case of long-term 
use.
Step V:   Weaning
Restart enteral feeding as soon as possible: individualize a step by step plan-basedduration PN, tolerance and level of ketosis.
Figure 1: Consensus flow chart of ketogenic diet parenteral nutrition (KD-PN) application. KD, ketogenic diet; IV, intravenous; TPN, total parenteral
nutrition; BMR, basal metabolic rate; RDA, recommended daily allowance; CVC, central venous catheter; PN, parenteral nutrition.
Ketogenic Diet Parenteral Nutrition Elles van der Louw et al. 7
monitoring of lipids and renal, cardiac, and liver func-
tioning.4
Limited data have been published in this area.14,16–19
The White Paper on ketogenic diet includes brief recom-
mendations on KD-PN monitoring.20
Results from our international survey show a wide range
of laboratory parameters (e.g. glucose, ketone levels, or
bicarbonate/carbon dioxide) that should be checked during
KD-PN and its frequency (Appendix S1).
An overview of recommendations for monitoring is
shown in Table IV.
Evaluation of risk–benefit
The evaluation of KD-PN is based on an assessment of
the efficacy, the ketosis, and side effects. When parenteral
administration is used in place of an already-commenced
KDT, the evaluation will be based on the maintenance of
seizure control. The seizure frequency based on a diary, as
well as on the electroencephalography (EEG) recordings in
some epilepsy syndromes, will be the main criteria for eval-
uating KD-PN.
Careful evaluation of the medical situation (i.e. underly-
ing disease, laboratory checks) is essential to ensure that
parenteral nutrition use is safe and to determine when ent-
eral KDT may be reintroduced.
When KD-PN is used for a refractory status epilepticus
including FIRES, appropriate criteria will be used (the
ability to stop an anesthetic agent, reduction of continuous
EEG discharges, cessation of seizures). When an anesthetic
agent is used to treat refractory status epilepticus, the use
of continuous EEG recording is required. Criteria to eval-
uate the efficacy should be both electroencephalographic
and clinical.
As mentioned above, the measurement of ketosis by b-
hydroxybutyrate levels is helpful in evaluating whether the
patient has the hallmarks of KDT. It could also be helpful
to evaluate the maintenance of ketosis after the switch
from enteral to parenteral administration or the appearance
of ketosis after initiation of KD-PN. The frequency of
monitoring ketosis will depend on the medical and nutri-
tional status of the patient. There are conflicting results in
the literature about the direct correlation of ketosis with
anti-seizure efficacy. Therefore, this should be considered
when initiating and managing parenteral ketogenic therapy:
ketosis is only used as a guide with improvement in clinical
symptoms/measures (e.g. seizure frequency or the ability to
reduce anesthesia) and not used as the primary guide in
establishing the effectiveness of ketogenic diet. If ketones
are low but the patient shows clinical benefit such as free-
dom from seizures, no further action is required.
Weaning from parenteral to enteral ketogenic diet
On the basis of the high-risk profile, limiting the period of
parenteral nutrition is highly important. When the under-
lying reason for nothing by mouth is solved, the enteral
route should be used immediately. Detailed information on
how the patient may be weaned from parenteral nutrition
is limited7,20 but stepwise tapering (one step at the time
with no diluted enteral feed) is likely to optimize tolerance
of enteral feed.7
In the literature there is little information about the
transition from KD-PN to enteral ketogenic diet. Some
studies only mention that enteral ketogenic diet is intro-
duced in a stepwise fashion without giving detailed infor-
mation.13,14,16,17
Results from our international survey show that weaning
is performed on an individual basis, with most centers
using a ketogenic formula as trophic feed and 33% using
medium-chain triglyceride oil (Appendix S1).
CONCLUSIONS
After two reminders the responder rate to our interna-
tional survey remained at 24 out of 150 (16%) and
might reflect the limited experience centers have.
Although there is a degree of variability in how interna-
tional expert teams practice, KD-PN consensual recom-
mendations have been reached on the most important
issues. Recommendations for safe and effective applica-
tion of KDT-PN have been established. Table II sum-
marizes these recommendations and Figure 1 provides an
overview of KD-PN application.
It is important to move to the next steps by providing
new data on KD-PN application. Obviously, prospective
and controlled studies are needed to prove the efficacy and
safety of KD-PN application based on these consensus rec-
ommendations. One of the first steps could be to consider
an international registry collecting the cases of patients
treated by KD-PN. More data would be helpful to update
these recommendations. Such an update is planned in the
next 5 years.
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